Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

231.89 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 231.89
Bid (Size) 100.00 (1)
Ask (Size) 271.85 (1)
Prev. Close 231.89
Today's Range 231.89 - 231.89
52wk Range 203.37 - 460.21
Shares Outstanding 50,396,622
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
From Charles River Laboratories, International Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022
Upgrades 
Via Benzinga

Performance

YTD
-35.96%
-35.96%
1 Month
+9.07%
+9.07%
3 Month
+0.30%
+0.30%
6 Month
-29.18%
-29.18%
1 Year
-44.26%
-44.26%

More News

Read More
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Recap: Charles River Q2 Earnings
Via Benzinga
Charles River Laboratories Announces Second-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
'I'm Going To Have To Say Avoid It': Jim Cramer Urges Waiting Before Buying This Tech Stock
Via Benzinga
Where Charles River Stands With Analysts
Via Benzinga
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Analyst Ratings for Charles River
Via Benzinga
Charles River: Q1 Earnings Insights
Via Benzinga
Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Via Benzinga
Charles River Laboratories Announces First-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Preview: Charles River's Earnings
Via Benzinga
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
From Charles River Laboratories International, Inc.
Via Business Wire
3 Top S&P 500 Stock Market Gainers Today: Coronavirus Vaccine Maker Moderna Jumps
Via Investor's Business Daily
Wells Fargo Maintains Overweight Rating for Charles River: Here's What You Need To Know
Via Benzinga
What 6 Analyst Ratings Have To Say About Charles River
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.